Semaglutide, the active ingredient in Ozempic and Wegovy, is a glucagon-like peptide-1 (GLP-1) receptor agonist taken as a ...

Introduction Sodium-glucose cotransporter 2 inhibitors (SGLT-2is) and glucagon-like peptide-1 receptor agonists (GLP-1RAs) are two classes of glucose-lowering drugs gaining popularity in the treatment ...

As weight loss jabs like Ozempic and Wegovy become ever more popular, doctors are growing increasingly concerned about their gnarly side effects. As Germany's Deutsche Welle notes, people who take ...

For people beginning their weight loss journey, a combination of physical activity and a healthy diet – such as the ...

Individualized ocular characteristics should be considered before starting GLP-1 RA therapies for weight loss and diabetes ...

SGLT2 inhibitors and GLP-1 receptor agonists lower cardiovascular risk in type 2 diabetes, but a recent review suggests that ...

GLP-1 RAs are associated with a modestly increased risk for GERD and gallstone disease but not with GI and biliary complications.

Some weight loss drugs may cause hair loss. While it’s typically a temporary side effect, it can affect your confidence.

GLP-1RAs were associated with improved quality of life and emotional eating behaviors among individuals with overweight and obesity.

GLP-1 drugs alter taste perceptions, challenging food makers to adapt by enhancing umami flavours, balancing sweetness, and ...

Weight-loss drugs have surged in popularity, promising rapid results with regular injections. Now, researchers from Japan ...

Objective Phase II trials suggest glucagon-like peptide-1 receptor (GLP1) agonists resolve metabolic dysfunction-associated steatohepatitis but do not affect fibrosis regression. We aimed to determine ...